Aventusoft L.L.C.

Aventusoft L.L.C. specializes in phonocardiographs, which are devices used to record and analyze heart sounds. These tools help clinicians assess cardiovascular function by capturing acoustic data from the heart, aiding in diagnostic evaluations.

Aventusoft L.L.C. is headquartered in the United States. The company’s location is relevant for understanding its regulatory framework and compliance context, particularly in the U.S. market.

Aventusoft L.L.C.’s devices, including the HemoTag, are listed in the FDA’s Unique Device Identifier (UDI) database. This registry helps track and identify medical devices authorized for use in the U.S., ensuring transparency and traceability.

Aventusoft L.L.C.’s devices fall under Class I regulatory classification in the U.S. This classification applies to devices posing the lowest risk to patients, often involving general controls like good manufacturing practices and labeling requirements.

The HemoTag is designed as a phonocardiograph to support cardiovascular assessments in clinical settings. By capturing and analyzing heart sounds, it assists healthcare providers in diagnosing conditions related to heart function, such as murmurs or arrhythmias.